Fibroblast News and Research

RSS

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children?

23 Dec 2014

U-M researchers devise reliable way to grow tumor cells

In a development that could lead to a deeper understanding of cancer and better early-stage treatment of the disease, University of Michigan researchers have devised a reliable way to grow a certain type of cancer cells from patients outside the body for study.

18 Dec 2014

Growth hormone worthwhile treatment in hypochondroplasia

Researchers report that recombinant human growth hormone can improve growth in children with hypochondroplasia.

30 Oct 2014

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other.

29 Oct 2014

Research shows FGF21 hormone acts directly on brain to regulate obesity

A hormone seen as a popular target to develop weight-loss drugs works by directly targeting the brain and triggering previously unknown activity in the nervous system, UT Southwestern Medical Center obesity researchers have found.

24 Oct 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.

29 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors.

17 Sep 2014

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.

26 Aug 2014

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows.

19 Aug 2014

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF).

17 Jul 2014

Personalized medicine for breast cancer patients may be just around the corner

For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.

16 Jul 2014

New method to help patients with cancer, genetic conditions, neurological disorders

UT Arlington physics researchers may have developed a way to use laser technology to deliver drug and gene therapy at the cellular level without damaging surrounding tissue. The method eventually could help patients suffering from genetic conditions, cancers and neurological diseases.

25 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report.

20 Jun 2014

Device used in physics and chemistry reveals dynamics of pervasive pathogen

If you have it, you probably don't know it. Cytomegalovirus, or CMV, is perhaps one of the biggest pathogens you've never heard of-big, both proportionately and epidemiologically.

6 Jun 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).